Brie Chun

About

Assistant Professor at Fred Hutchinson Cancer Center and University of Washington.
Breast oncology, focus on tumor immunology, immunotherapies

Employment

• Fred Hutch Cancer Center Assistant Professor
  2025 - Present
• Oregon Health & Science University Fellow, Hematology & Oncology
  2022 - 2025
• Earle A. Chiles Research Institute Fellow, Immuno-oncology
  2020 - 2021
• Providence Portland Medical Center Resident
  2017 - 2020

Education

• University of Virginia MD
  2013 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (13)

• Vaccines for Cancer
  JAMA 2026 DOI: 10.1001/jama.2026.15540
  +Save
• Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion
  The Oncologist 2025 DOI: 10.1093/oncolo/oyaf093
  +Save
• Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
  The Oncologist 2023 DOI: 10.1093/oncolo/oyad035
  +Save
• A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
  David B. Page, Joanna Pucilowska, Brie Chun +25 more
  npj Breast Cancer 2023 DOI: 10.1038/s41523-023-00541-2
  +Save
• A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
  2022 DOI: 10.21203/rs.3.rs-1954085/v1
  +Save
• Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
  Brie Chun, Joanna Pucilowska, Shu‐Ching Chang +14 more
  Journal for ImmunoTherapy of Cancer 2022 DOI: 10.1136/jitc-2021-004033
  +Save
• 1665 - QuPath versus InForm: Digital image analysis of multiplex immunofluorescence (mIF) tumor-infiltrating lymphocyte (TIL) outcomes in an immunotherapy clinical trial
  AACR 2021
  +Save
• Abstract PS17-07: Impact of chemotherapy (chemo) on t-cell maturation and clonal proliferation in early-stage and metastatic breast cancer
  Poster Session Abstracts 2021 DOI: 10.1158/1538-7445.sabcs20-ps17-07
  +Save
• A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
  Frontiers in oncology 2021
  +Save
• Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
  Breast cancer research : BCR 2021 DOI: 10.1186/s13058-020-01378-4
  +Save
• Combination Immunotherapy Strategies in Breast Cancer
  Current Breast Cancer Reports 2019 DOI: 10.1007/s12609-019-00333-3
  +Save
• A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).
  Journal of Clinical Oncology 2019 DOI: 10.1200/jco.2019.37.15_suppl.tps1106
  +Save
• Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
  Journal of Clinical Oncology 2019 DOI: 10.1200/jco.2019.37.15_suppl.1015
  +Save